BioPhorum produces landmark best practices guide for evaluating leachables risk

BioPhorum produces landmark best practices guide for evaluating leachables risk

  • Home
  • News and Papers
  • BioPhorum produces landmark best practices guide for evaluating leachables risk

BPOG’s Leachables team has just published an Industry Best Practice Guide: Best practices guide for evaluating leachables risk from polymeric single-use systems used in biopharmaceutical manufacturing. The Guide presents a practical and adaptable approach for assessing single-use systems (SUS) for the leachables risks they present to biopharmaceutical product quality and patient safety.

Independent industry surveys have shown that concerns about extractables and leachables are the number one barrier to implementing disposables technologies1. There is clear regulatory guidance around what is required by regulatory authorities such as the EMA2 yet to date there has been limited or no information (consensus or best practice) on how companies should do this.

The best practices guide for evaluating leachables risk from polymeric single-use systems used in biopharmaceutical manufacturing represents the consensus position of this team of experts and key opinion leaders from 17 major biopharmaceutical companies. The guide is in 4 sections focused on risk assessment, leachables study design, analytical methods and lessons learned from experience.  Key drivers for the guide were ensuring product quality and patient safety during the adoption of single use systems.

According to Laszlo Litauszki, Head of Material Qualification Biologics & Small Molecule at Shire ‘The BPOG guide will establish a science-based industry common practice to assess the risk a Single Use System poses on drug product quality from the leachables perspective, providing a common approach to users and regulators.  It maintains the flexibility the industry needs by identifying critical concepts to consider for this Risk Assessment’.

The use of disposables in biopharmaceutical manufacturing has grown significantly over the last two decades and regulators require that companies assess & manage any risk posed to drug substance or drug product by disposable systems. Typically, this is done by evaluating leachables data and/or performing leachables studies as required to cover the unit operations used in the process. Extractables data can be used to inform this leachables assessment and make data based choices when selecting equipment.  At the time the Extractables and Leachables teams were formed, there was no standard for extractables testing available. This lead to each end-user company taking its own approach and in turn similar, but different requirements. In turn, suppliers performed different testing depending on prior experience and requests from their customer base making comparison and development of best practice challenging. The work of the team was to influence change and create a standard for extractables testing which they did when they launched the Extractables Protocol in 2014.   This protocol is currently being successfully implemented as a user requirement by a number of major biopharmaceutical manufacturing companies.

Many disposables suppliers are now following the BPOG Extractables Protocol which provides the drug substance manufacturers with vital information when performing a leachables risk assessment. By providing a complete data package generated using a standardized protocol, and presented in a standard way it can be envisaged that end users will be able to qualify new equipment much more rapidly and without need to revert to the supplier for additional information.  Essentially this approach allows the manufacturer to make appropriate selection of SUS products and determine what to look out for in terms of leachables. This helps to ensure that patient safety is not compromised and at the same time offers the possibility of reduced waste and increased flexibility within the industry.

It is the responsibility of the end user or drug substance manufacturer to give consideration to the nature and amount of potential leachables. This consideration would typically include a risk assessment and performing of leachables studies as necessary. Historically there has been no guidance as to how this leachables risk assessment or studies should be conducted resulting in varying approaches.   In January 2015, the Extractables and Leachables team set out on the journey to create leachables guidance with the goal of developing a set of practical and adaptable core principles to manage leachables effectively and efficiently.

The best practices outlined in the guide will not only help to standardize approaches to identifying and investigating leachables risks, they also build on the extractables protocol previously published by BPOG and demonstrate how (supplier) extractables data is used by the bioprocess industry. Furthermore, standardization of leachables testing and extractables testing is a key cornerstone to allowing more rapid and widespread adoption of single-use technologies, an area of focus in BPOG’s forward-looking Technology Roadmap. Ultimately, in addition to ensuring best practice in regard to assessing leachables impact on product quality and patient safety, this work will help to support increased security of supply and reduced costs to patients.

1. Smalley, C. et al. Best Practices for Leachables Under Development. PDA Letter (2016).

2. European Medicines Agency. Guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission Guideline on process validation for the manufacture of biotechnology-derived active substances and data to. EMA/CHMP/B, 1–13 (2016).

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Proactive prioritization: a new tool for assessing raw material risk

The Raw Material Risk Management workstream has launched a new, raw material risk assessment tool aimed at helping industry identify and prioritize around the challenging[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More